Precipio, Inc. Hits New 52-Week High of $28.50, Up 345.57%

Precipio, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 28.50 on November 20, 2025. This achievement marks a remarkable increase from its 52-week low of USD 3.90, showcasing a substantial year-over-year performance of 345.57%.
With a market capitalization of USD 34 million, Precipio operates in a competitive industry where it has demonstrated notable resilience and growth. The company's financial metrics reflect its current standing, with a price-to-book ratio of 2.77 and a debt-to-equity ratio of -0.05, indicating a unique financial structure. However, it is important to note that the company is currently loss-making, as evidenced by the absence of a price-to-earnings ratio and a return on equity of -15.82%.

As Precipio continues to navigate the dynamic landscape of the pharmaceuticals and biotechnology industry, its recent performance underscores its potential within the market.